Dendritic cell engineered cTXN as new vaccine prospect against L. donovani. (September 2021)

• Record Type: Journal Article
• Authors: Suman, Shashi S.; Kumar, Akhilesh; Singh, Ashish K.; Amit, Ajay; Topno, R.K.; Pandey, K.; Das, V.N.R.; Das, P.; Ali, Vahab; Bimal, Sanjiva
• Is Part Of: Cytokine. Volume 145(2021)
• Publication Date: 2021-09
• Subjects: Visceral leishmaniasis -- cTXN -- Dendritic cells -- Macrophages -- IL-10 -- IFN-γ -- GM-CSF -- NFκβ -- Vaccine; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2020.155208
• Languages: English
• ISSNs: 1043-4666

Abstract

Abstract: Dendritic cells (DCs), as antigen-presenting cells, can reportedly be infected with Leishmania parasites and hence provide a better option to trigger T-cell primary immune responses and immunological memory. We consistently primed DCs during culture with purified recombinant cytosolic tryparedoxin (rcTXN) and then evaluated the vaccine prospect of presentation of rcTXN against VL in BALB/c mice. We reported earlier the immunogenic properties of cTXN antigen derived from L. donovani when anti-cTXN antibody was detected in the sera of kala-azar patients. It was observed that cTXN antigen, when used as an immunogen with murine DCs acting as a vehicle, was able to induce complete protection against VL in an infected group of immunized mice. This vaccination triggered splenic macrophages to produce more IL-12 and GM-CSF, and restricted IL-10 release to a minimum in an immunized group of infected animals. Concomitant changes in T-cell responses against cTXN antigen were also noticed, which increased the release of protective cytokine-like IFN-γ under the influence of NF-κβ in the indicated vaccinated group of animals. All cTXN-DCs-vaccinated BALB/c mice survived during the experimental period of 120 days. The results obtained in our study suggest that DCs primed with cTXN can be used as a vaccine prospect for the control of visceral leishmaniasis.